NCT00720304 · OUTCOME

Overall Survival (OS)

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck · Source last updated 2024-08-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percent
Interval / dispersion: Not reported
Time frame: 3 years

What was measured

Percent of participants alive at follow-up time. Overall survival time is evaluated from the date of treatment to date of death, and to date of last follow-up for those still alive.

Analysis population: Participants enrolled in study

Groups in this outcome

Oral Erlotinib Hydrochloride

docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Oral Erlotinib Hydrochloride	43

Reported measurements

Source class 1

Values in Percent · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Oral Erlotinib Hydrochloride	81	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
81

denoms

counts
group Id
OG000
value
43
units
Participants

description

Percent of participants alive at follow-up time. Overall survival time is evaluated from the date of treatment to date of death, and to date of last follow-up for those still alive.

groups

description
docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
id
OG000
title
Oral Erlotinib Hydrochloride

param Type

NUMBER

population Description

Participants enrolled in study

reporting Status

POSTED

time Frame

3 years

title

Overall Survival (OS)

type

SECONDARY

unit Of Measure

Percent

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice